Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

* To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4).
* To document pharmacokinetics of SAR302503 after repeated 500 mg oral daily doses.

Secondary Objectives:

* To assess the safety profile of 15-day repeated oral doses of 500 mg SAR302503 in Segment 1
* To characterize the safety and tolerability of 28-day consecutive doses of 500 mg SAR302503 in Segment 2
* To determine antitumor activity in Segment 2

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

NCT06215430

Healthy

COMPLETED PHASE1

Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

NCT05581992

Healthy Participants

COMPLETED PHASE1

A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

NCT05392127

Rheumatoid Arthritis

COMPLETED PHASE1

A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects

NCT05041920

Tumor

COMPLETED PHASE1

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

NCT03363815

Heathy Volunteer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The duration of the study for an individual patient will include a period to assess eligibility (screening period 21 days), followed by a treatment period of at least 15 days of study treatment, and an end-of-treatment visit at least 30 days following the last administration of study drug. However, treatment may continue if patients are receiving benefit and do not have unacceptable toxicity or meet study withdrawal criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Segment 1

two single doses of omeprazol/metoprolol/midazolam on day-1 and day 15 without food, SAR302503 500 mg once daily without food for 15 days

Group Type EXPERIMENTAL

SAR302503

Intervention Type DRUG

Pharmaceutical form:capsule

Route of administration: oral

omeprazol

Intervention Type DRUG

Pharmaceutical form:capsule

Route of administration: oral

metoprolol

Intervention Type DRUG

Pharmaceutical form:tablet

Route of administration: oral

midazolam

Intervention Type DRUG

Pharmaceutical form:solution

Route of administration: oral

Segment 2

SAR302503 500 mg once daily without food in 28-day per cycle

Group Type EXPERIMENTAL

SAR302503

Intervention Type DRUG

Pharmaceutical form:capsule

Route of administration: oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SAR302503

Pharmaceutical form:capsule

Route of administration: oral

Intervention Type DRUG

omeprazol

Pharmaceutical form:capsule

Route of administration: oral

Intervention Type DRUG

metoprolol

Pharmaceutical form:tablet

Route of administration: oral

Intervention Type DRUG

midazolam

Pharmaceutical form:solution

Route of administration: oral

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist
* Signed informed consent

Exclusion Criteria

* Less than 18 years of age.
* Limited physical functioning (as evaluated by the Eastern Cooperative Oncology Group (ECOG) scale)
* Inability to follow study requirements and schedule
* Treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other anti-cancer therapy
* Serious medical illness at same time of study and/or significantly abnormal lab reports
* Lack of pregnancy contraception (women of childbearing potential), pregnancy, or breast feeding.
* Men who partner with a woman of childbearing potential, unless they agree to use effective contraception while on study drug
* Continued toxic effects of prior chemotherapy
* Evidence of other concurrent active malignancy
* Other concurrent serious illness or medical condition
* Cardiac abnormalities include bradycardia, AV block or other conduction defect on ECG, and patients taking a beta blocker.
* Patients with Insulin-Dependent Diabetes Mellitus.
* Patients with known active (acute or chronic) hepatitis A, B, C, and hepatitis B and C carries. Prior history of chronic liver disease (e.g., chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis \[NASH\]).
* Inadequate organ function
* History of partial or total gastrectomy, or, if in the opinion of the investigator, have any other disorder that would inhibit absorption of oral medications.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No